Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Erwann Loret

Erwann Loret

Aix-Marseille University, France

Title: A reasonable hope to cure HIV with the Tat Oyi vaccine: Results and follow up of a double blinded randomized phase I/IIa clinical trial in France

Biography

Biography: Erwann Loret

Abstract

We know that it was possible to cure from HIV for at least one patient called the “Berlin patient”. Although the hematopoietic stem cell transplantation that saves him was not reproducible, his cure from HIV was well documented and shows that two steps are required. The first step is that the HIV DNA in peripheral blood becomes and stays undetectable. The second step is a significant decrease of antibodies against HIV-1 (never observed in HIV infected patients under successful cART) called retroseroconversion. BIOSANTECH was the sponsor of a phase I/II clinical trial carried out at Marseille on 48 HIV infected volunteers under cART with the Tat Oyi vaccine (Loret et al., Retrovirology 2016). These volunteers were randomized in double-blind method into four groups (n=12) and three intradermal injections were made with respectively for each group 0, 11, 33, or 99ug of a synthetic Tat Oyi protein in buffer without adjuvant at times designated by month 0 (M0), M1 and M2. The volunteers then underwent a one month cART interruption at M5. The vaccine reduces of 1.5 log copies/ml the HIV rebound median compare to the placebo group. Furthermore no increase of HIV infected cells was observed following cART interruption (p=0.001). A follow up of volunteers three years after vaccination shows that vaccinated volunteers who were HIV DNA undetectable at the end of the trial are still undetectable and the number of HIV DNA undetectable increased in all groups excepted in the placebo group (Fig 1). Preliminary results show that retroseroconversion begins in two volunteers.

HIV DNA medians in peripheral blood for each group. Volunteers with undetectable HIV DNA (< 20 copies/ 106 PBMC) were counted as having 19 copies, which is 1.3 log copies/ml (dashed line). The placebo group is depicted as a black square, the 11 μg group as a black circle, the 33 μg group as a white square and the 99 μg group as a white circle.

Figure 1: HIV DNA medians in peripheral blood for each group.